Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wish he would share what he's hearing as well.
Sorry I meant I was buying more regardless of this info but now for sure I will.
Just heard at my daughters christening that Stryker may be looking to buy Titan or Mazor. Info came from a family member that works for Medtronics.
Anyone hearing anything else like this?
I'll be buying more at the open as I wasn't going to buy more before I heard this news.
I disagree. How do you figure that valuation?
News out!!
SAN FRANCISCO - July 17, 2014 - Merriman Capital, Inc. ("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc. (MERR), announced that it has initiated equity research coverage of Milestone Scientific, Inc. (MLSS) with a Buy rating and a $3.00 price target.
Milestone Scientific`s injection technology for the medical and dental markets can uniquely identify the tissue targeted for injection. This proprietary technology ensures the practitioner knows the location of the tip of the needle in real-time. This ability should have broad repercussions in the medical community. Clinical evidence for Milestone`s core technology has demonstrated potential benefits for a variety of applications, including epidurals, intra-articular injections, colorectal surgery, podiatry, dermatology, nasal/sinus surgery, hair transplant and cosmetic surgery. Milestone Scientific has 24 issued patents and has won a number of awards over the past three years in the dental community, where Milestone currently derives its revenue. In dentistry, it is the first major breakthrough in injection technology since the invention of the hypodermic syringe in the 1860s. Milestone is awaiting FDA and CE approval for its epidural and intra-articular instruments.
CLICK HERE FOR FULL REPORT
About Merriman Capital, Inc.
Merriman Capital, Inc. is a full service investment bank and Broker-Dealer that facilitates efficient capital formation through a proprietary digital network, and offers Capital Markets Advisory and comprehensive Corporate Brokerage services for public and private companies. The firm also provides equity and options execution services for sophisticated investors and differentiated research for high growth companies. Merriman Capital, Inc. is a wholly owned brokerage subsidiary of Merriman Holdings, Inc. (MERR) and is a leading advisory firm for publicly traded, high-growth companies.
Digital Capital Network, powered by Merriman Capital, is a capital marketplace that enables highly targeted and more efficient execution of transactions. Please visit our website for more information on how you can be a part of our Digital Capital Network: http://www.digitalcapitalnetwork.com.
Merriman Capital, Inc. is a registered broker-dealer and member of The Financial Industry Regulatory Authority (FINRA) http://www.finra.org/ and the Securities Investor Protection Corporation (SIPC) http://www.sipc.org/.
Note to Investors
This press release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed on March 31, 2014. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "should," and "would" or similar words. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise. The Form 10-K filed on March 31, 2014, together with this press release and the financial information contained herein, are available on our website, www.merrimanco.com. Please click on "Investor Relations."
# # #
At Merriman:
Agreed
Another buying opportunity before he reserves are announced!!!
Thank you.
Is the gold going to be 14k, 18k or 24k and will that make a difference on the buyout price.
Ok that was meant to make you laugh!
Oh thank you someone represented that last week as well.
I went to the link but can't follow who owns the 100k please advise.
Does anyone know if the Ukrainian report will be delivered in English?
Crazy for not putting in the other 30k IMHO.
I bought 7000 more in the last 2 days hoping we go up from here, I'm happy to find out I didn't buy them from chickenlips and CUIN.
I was losing my sanity for a while there without you guys.
Sidelines is for losers put me in coach I'm ready to play!
Has anyone heard from CUIN or was he asked to put down his level 2 down for a month?
Come out and play with the other degenerates please?
Thank you, I'm thinking they will surprise us and be on time.
Anyone have an estimate or guess when the reserves will be released?
I sold out today 4 machine in the quarter is not what I was looking for.
Agreed
Heavy and holding. Hoping the reserves are great.
Welcome to the board how did you hear about Uspr?
Old news bro but thanks.
I sold 20000 at .19 that I bought at .125.
Next!
Mazor Robotics Reports Orders for Four Renaissance Systems During the Second Quarter of 2014
Mazor Robotics Ltd. (TASE:MZOR; NASDAQ GM:MZOR), a developer of innovative guidance systems and complementary products, announced today that it received orders for and delivered four Renaissance systems, two in the U.S. and two in international markets, in the second quarter which ended June 30, 2014. Of the four systems, one included the recently launched brain surgery module.
Today’s announcement was made in accordance with Mazor Robotics’ disclosure policy of announcing the total number of Renaissance systems orders in the quarter immediately after the end of the quarter. Mazor Robotics will announce the second quarter financial results in early August.
“Interest on the part of surgeons to acquire the Renaissance system reached all time highs, and clinical results from the use of our system continue to be outstanding. As a result, our system order pipeline remains strong,” said Ori Hadomi, CEO of Mazor Robotics. “The first U.S. commercial order of our recently released brain surgery module from a new customer as part of its Renaissance installation represents a new milestone for Mazor. The brain application is gaining interest with new and existing customers. During the quarter we faced extended administrative approval processes for system orders by additional potential customers. We currently expect these additional system orders to be concluded during the second half of the year.”
About Mazor
Mazor Robotics is dedicated to the development and marketing of innovative surgical guidance systems and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance®, is a state-of-the-art surgical guidance system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 45,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding interest on the part of surgeons to acquire the Renaissance system continuing to reach all time highs, that our system order pipeline remains strong, that the brain application is gaining interest with new and existing customers, and that system sales by additional potential customers are expected to conclude beyond quarter end, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC) including those discussed under the heading "Risk Factors" in Mazor’s annual report on Form 20-F filed with the SEC on April 9, 2014 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
U.S.
EVC Group
Investors:
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
or
Robert Jones, 646-201-5447
bjones@evcgroup.com
or
Media:
David Schemelia, 646-201-5431
dave@evcgroup.com
or
John Carter, 212-850-6021
jcarter@evcgroup.com;
Usprinvestor and info, predictions or ideas for today leading into the holiday weekend?
Larryinvest I totally agree this article will knock him out of the business and a job. Nothing he stated makes any sense.
I don't care where the helium comes from as long as the balloon continues to soar!
Get on board now the train is leaving the station.
Big news imminent. Which is back up a higher share price.
Titan Medical Inc. Corporate Update
Titan Medical Inc. Corporate Update
TORONTO, ONTARIO--(Marketwired - Jun 30, 2014) - Titan Medical Inc. (the "Company") (TSX-VENTURE:TMD) (OTCQX:TITXF) announced today that Mr. Joe Talarico, Senior Vice President Business Development has resigned his position with the Company. We would like to thank Joe for his contribution to Titan during his four years with the Company. In the interim John Hargrove, Chairman and CEO will assume the responsibilities for Business Development.
About Titan Medical Inc.
Titan Medical Inc. is a Canadian public company (TSX-VENTURE:TMD) (OTCQX:TITXF) focused on the design and development of a robotic surgical system for application in minimally invasive surgery ("MIS"). The Company's robotic surgical system, currently under development, comprises a surgeon-controlled robotic platform that includes a 3D vision system and interactive instruments for performing MIS procedures, and a surgeon workstation that provides the surgeon with an interface to the robotic platform for controlling the interactive instruments and providing a 3D endoscopic view of inside a patient's body during MIS procedures. The robotic surgical system is being designed to expand robotic surgery into areas of surgical specialties and simple and complex procedures that are currently under-serviced, and to allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. For more information, visit the Company's website at www.titanmedicalinc.com.
Forward Looking Statements
This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors" section of the Company's Annual Information Form dated April 4, 2014 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Titan Medical Inc.
John T. Hargrove
Chairman and Chief Executive Officer
(416) 548-7522 (ext. 151)
john.hargrove@titanmedicalinc.com
www.titanmedicalinc.com
I thought this was a great article we just need some new investors to join this board, thank you for posting.
Yes that I know I'm sorry I meant human tissue testing? That would drive the stock up in my opinion significantly and help to get up lifted.
CUIN and idea when tissue testing is due to start? That's would be big, have a great weekend.
Thanks for all your input.
I think we had a great week and a great finish. I really have a feeling that when the new IR firms takes over that we will see some kind of press release the first week they take over on 7/7/14, it just makes sense to me. They would have been working behind the scenes for almost three weeks to make something happen and continue this trend.
If I were paying them 20,000 a month I would demand it, that's make something happen kind of money IMHO.
Anyone agree?
Stocks now acting like we may see good news shortly.
Wow maybe there is a spot for Mr Berry to join the board?
We just need some follow through tomorrow and were on our way!
Funny but your just upset you sold the recent bottom.
That doesn't surprise me as they probably gave him a hefty amount of shares so if this hits it would make no sense to stay and leave that on the table IMHO, and he probably feels it's a winner as I do.
I have 20 plus years experience in the brokerage industry and I completely agree with you, this type of stock trades on anticipated future earnings prior to the revenue and FDA approvals IMHO.
I would hate to see you being negative if that comment wasn't!
I 100 percent agree with you Trucker and when the reserve results come in shortly they will find something negative about that as well.
Late afternoon rally into the close would be so nice.